Malaysian Civil Society Groups Seek Compulsory License for Second Line HIV/AIDS Medicine

 Posted by on May 22, 2012  No Responses »
May 222012
 

Earlier this month, the Malaysian AIDS council, an umbrella group of 49 civil society groups, asked the Malaysian Minister of Health to begin a government sponsored program to provide second line treatment to people with HIV/AIDS.  In order to make this feasible, the Council requests that the Ministry grant a compulsory license for government use under Section 84 of the Patents Act for patents related to Lopinavir+Ritonavir, an important antiretroviral sold under the brand name Kaletra by Abbott.    Continue reading »

FacebookTwitterRedditStumbleUponWordPressTumblrBlogger PostEmailPrintFriendlyShare

Brazil Fast Tracks Follow-On Kaletra Patent; GTPI Files Pre-Grant Opposition

 Posted by on December 22, 2011  No Responses »
Dec 222011
 

The Brazilian Instituto nacional da Propriedade Industrial announced it will fast track its decision on whether or not to grant patents on the heat-stablized versions of lopinavir+ritonavir (brand names: Kaletra, Aluvia) and ritonavir (Norvir). Both drugs are important antiretroviral drugs recommended by the World Health Organization for HIV/AIDS treatment in resource-poor settings.  If the follow on patents are granted, they will not expire until 2024. Continue reading »

FacebookTwitterRedditStumbleUponWordPressTumblrBlogger PostEmailPrintFriendlyShare